Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients
NCT ID: NCT07321613
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
545 participants
OBSERVATIONAL
2023-05-01
2025-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
NCT07309419
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
NCT00921531
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT04954781
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
NCT06911255
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
NCT01102335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TACE+cocktail
Patients in the TACE+cocktail group received TACE and took the combined oral medications daily, which consisted of thalidomide tablets, carmofur tablets , and compound mylabris capsule.
Thalidomide (50mg)
Thalidomide tablets (Changzhou Pharmaceutical Factory, 50 mg qn)
carmofur
carmofur tablets (Qilu Pharmaceutical, 100 mg, tid)
compound mylabris capsule
CMC (Guizhou Yibai Pharmaceutical Co., Ltd, 750 mg, bid)
TACE
received initial treatment with traditional TACE by well-trained and experienced physicians
TACE only
Patients in the TACE only group received only TACE treatment.
TACE
received initial treatment with traditional TACE by well-trained and experienced physicians
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thalidomide (50mg)
Thalidomide tablets (Changzhou Pharmaceutical Factory, 50 mg qn)
carmofur
carmofur tablets (Qilu Pharmaceutical, 100 mg, tid)
compound mylabris capsule
CMC (Guizhou Yibai Pharmaceutical Co., Ltd, 750 mg, bid)
TACE
received initial treatment with traditional TACE by well-trained and experienced physicians
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients underwent conventional TACE.
* availability of complete medical records for data extraction and follow-up.
Exclusion Criteria
* poor liver functions (Child-Pugh class C).
* accompanying other life-threatening diseases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20251111101713560
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.